Thumbnail Image
Item

Dose-escalated adaptive radiotherapy for bladder cancer: results of the phase 2 RAIDER randomised controlled trial

Huddart, R.
; 
Hafeez, S.
; 
Griffin, C.
; 
Choudhury, A.
; 
Foroudi, F.
; 
Syndikus, I.
; 
Hindson, B.
; 
Webster, A.
; 
McNair, H.
; 
Birtle, A.
... show 10 more
Citations
Google Scholar:
Lookup
Altmetric:
Abstract
Background and objective: Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the safety of such a schedule. Methods: RAIDER is an international phase 2 noncomparative randomised controlled trial (ISRCTN26779187). Patients with unifocal T2-T4a urothelial bladder cancer were randomised (1:1:2) to standard whole bladder radiotherapy (WBRT), standard-dose adaptive radiotherapy (SART), or dose-escalated adaptive radiotherapy (DART). Two fractionation (f) schedules recruited independently. WBRT and SART dose was 55 Gy/20f or 64 Gy/32f, and DART dose was 60 Gy/20f or 70 Gy/32f. For SART and DART, a radiotherapy plan (small, medium, or large) was chosen daily. The primary endpoint was the proportion of patients with radiotherapy-related late Common Terminology Criteria for Adverse Events grade >= 3 toxicity; the trial was designed to rule Key findings and limitations: A total of 345 patients were randomised between October 2015 and April 2020: 41/46 WBRT, 41/46 SART, and 81/90 DART patients in the 20f/32f
Authors
Huddart, R.
Hafeez, S.
Griffin, C.
Choudhury, A.
Foroudi, F.
Syndikus, I.
Hindson, B.
Webster, A.
McNair, H.
Birtle, A.
Varughese, M.
Henry, A.
McLaren, D.
Parikh, O.
Nikapota, A.
Tang, C. L.
Patel, E.
Miles, E.
Warren-Oseni, K.
Kron, T.
Hill, C.
Philipps, L.
Vassallo-Bonner, C.
Cheung, K. C.
Gribble, H.
Lewis, R.
Hall, E.
Affiliation
Inst Canc Res, Sutton, England Royal Marsden NHS Fdn Trust, Sutton, England Christie NHS Fdn Trust, Manchester, England Austin Hlth, Heidelberg, Vic, Australia Clatterbridge Canc Ctr, Bebington, England Christchurch Hosp, Canterbury Reg Canc & Haematol Serv, Christchurch, New Zealand Univ Coll Hosp, London, England Univ Coll Hosp, Univ Coll Hosp NHS Fdn Trust, London, England Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Rosemere Canc Ctr, Preston PR2 9HT, Lancs, England Univ Manchester, Manchester, England Univ Cent Lancashire, Preston, England Royal Devon & Exeter NHS Fdn Trust, Royal Devon & Exeter Hosp, Exeter, England Univ Leeds, Leeds, England St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, England Western Gen Hosp, NHS Lothian, Edinburgh, Scotland Royal Sussex Cty Hosp, Brighton & Sussex Univ Hosp NHS Trust, Brighton, England Sir Charles Gairdner Hosp, Nedlands, WA, Australia Mt Vernon Hosp, Natl Radiotherapy Trials Qual Assurance Grp RTTQA, Northwood, England Peter Maallum Canc Ctr, Melbourne, Vic, Australia TROG Canc Res, Waratah, NSW, Australia
Description
Date
2025
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Found from Unpaywall
Adobe PDF, 2.13 MB
Keywords
Type
Article
Citation
Huddart R, Hafeez S, Griffin C, Choudhury A, Foroudi F, Syndikus I, et al. Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial. EUROPEAN UROLOGY. 2025 JAN;87(1):60-70. PubMed PMID: WOS:001388452400001. English.
Journal Title
Journal ISSN
Volume Title
URI
https://christie.openrepository.com/handle/10541/627672
Embedded videos